Literature DB >> 2822432

Electroconvulsive shock but not antidepressant drugs increases alpha 1-adrenoceptor binding sites in rat brain.

C A Stockmeier1, S W McLeskey, J A Blendy, N R Armstrong, K J Kellar.   

Abstract

Treatment of rats with electroconvulsive shock once daily for 10-12 days increased the density of alpha 1-adrenoceptors labeled by [3H]prazosin in homogenates of frontal cerebral cortex. A single treatment did not affect [3H]prazosin binding. Repeated treatment with electroconvulsive shock did not appear to affect alpha 1-adrenoceptor binding in the hippocampus or hypothalamus. Treatment of rats with reserpine also increased [3H]prazosin binding in the frontal cortex. In contrast to electroconvulsive shock, three weeks administration of tricyclic antidepressant drugs, monoamine oxidase inhibitors, or atypical antidepressant drugs did not significantly affect [3H]prazosin binding sites in the frontal cortex. The affinities of antidepressant drugs for alpha 1-adrenoceptors ranged from about 50 nM for tricyclic and atypical antidepressants to about 100 microM for monoamine oxidase inhibitors. The high affinities of the tricyclic and atypical antidepressant drugs for alpha 1-adrenoceptors could contribute to clinical differences between these classes of drugs and monoamine oxidase inhibitors. Furthermore, the electroconvulsive shock-induced increase in alpha 1-adrenoceptors could contribute to differences in clinical effects between this treatment and antidepressant drugs.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2822432     DOI: 10.1016/0014-2999(87)90582-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Effects of chronic antidepressant treatment on alpha 1- and alpha 2-adrenoceptors in the rat anococcygeus muscle.

Authors:  E Vila; J Sallés; A Badia
Journal:  J Neural Transm Gen Sect       Date:  1990

Review 2.  Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system.

Authors:  G B Baker; A J Greenshaw
Journal:  Cell Mol Neurobiol       Date:  1989-03       Impact factor: 5.046

3.  Sertraline and cocaine-induced locomotion in mice. I. Acute studies.

Authors:  M E Reith; H L Wiener; C T Fischette
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Differential modulation of α-1 adrenoceptor subtypes by antidepressants in the rat brain.

Authors:  D Ramakrishna; M N Subhash
Journal:  J Neural Transm (Vienna)       Date:  2010-12-07       Impact factor: 3.575

5.  The effect of reserpine, desipramine and thyroid hormone on alpha 1a- and alpha 1b-adrenoceptor binding sites: evidence for a subtype-specific regulation.

Authors:  G Hanft; G Gross
Journal:  Br J Clin Pharmacol       Date:  1990       Impact factor: 4.335

6.  Oxaprotiline enantiomers given repeatedly and brain alpha-adrenoceptors.

Authors:  J Maj; K Wedzony; V Klimek; Z Rogóz; G Skuz
Journal:  J Neural Transm Gen Sect       Date:  1990

7.  Effects of antidepressant drugs on inositol phospholipid hydrolysis in rat cerebral cortical slices.

Authors:  L E Dyck; A A Boulton
Journal:  Neurochem Res       Date:  1989-11       Impact factor: 3.996

8.  A comparison of various antidepressant drugs demonstrates rapid desensitisation of alpha 2-adrenoceptors exclusively by sibutramine hydrochloride.

Authors:  D J Heal; M R Prow; J Gosden; G P Luscombe; W R Buckett
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  Assessment of rat brain alpha 1-adrenoceptor binding and activation of inositol phospholipid turnover following chronic imipramine treatment.

Authors:  P P Li; J J Warsh; D Sibony; A Chiu
Journal:  Neurochem Res       Date:  1988-12       Impact factor: 3.996

10.  The effect of acute and chronic electroconvulsive shock on [3H]phorbol-dibutyrate binding to rat brain membranes.

Authors:  C H Gleiter; J Deckert; D J Nutt; P J Marangos
Journal:  Neurochem Res       Date:  1988-11       Impact factor: 3.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.